Background
Dates of data collection | August–September 2009 |
Sample
|
N
|
Outlets screened | 2368 |
Outlets interviewed | 778 |
Among all screened outlets, percentage that had
|
% (95% CI)
|
Public sector availability of quality-assured ACT | 48.5 (32.8, 64.6) |
Private sector availability of quality-assured ACT | 14.1 (10.6, 18.6) |
Public sector availability of non quality-assured ACT | 20.0 (11.4, 32.8) |
Private sector availability of non quality-assured ACT | 60.7 (55.2, 66.0) |
Public sector availability of oral artemisinin monotherapy | 26.0 (15.4, 40.3) |
Private sector availability of oral artemisinin monotherapy | 70.4 (65.4, 75.0) |
Anti-malarial market share
|
%
|
Market share of oral artemisinin monotherapy | 10.8 |
Methods
Design and sample
Procedures
Measures
Data analysis
Results
N | Public sector | Private sector | ||||||
---|---|---|---|---|---|---|---|---|
Public facility | Private not-for-profit facility | Private for-profit facility | Pharmacy | Drug store | General retailer | Itinerant drug vendor | ||
Outlets screened | 3364 | 26 | 66 | 367 | 3 | 741 | 2149 | 12 |
Eligible outlets | ||||||||
Anti-malarial in stock | 962 | 21 | 41 | 174 | 3 | 722 | 1 | 0 |
Anti-malarial in stock in the past 3 monthsa
| 45 | 4 | 6 | 28 | 0 | 10 | 0 | 0 |
Malaria testing availablea
| 142 | 4 | 16 | 122 | 0 | 0 | 0 | 0 |
Outlets interviewed | ||||||||
Anti-malarial in stock in the past 3 monthsa
| 932 | 21 | 41 | 173 | 3 | 693 | 1 | 0 |
Malaria testing availablea
| 45 | 1 | 6 | 28 | 0 | 10 | 0 | 0 |
Malaria testing available | 141 | 4 | 16 | 121 | 0 | 0 | 0 | 0 |
Products audited | ||||||||
Anti-malarials | 12,291 | 109 | 169 | 815 | 85 | 11,111 | 2 | 0 |
Malaria RDTs | 278 | 8 | 13 | 54 | 1 | 3 | 0 | 0 |
Anti-malarial market composition
Availability of anti-malarials
Anti-malarial market share
Non quality-assured ACT in the private for-profit sector
Price of anti-malarials
Readiness for malaria case management: availability of quality-assured ACT and malaria diagnosis, and availability of intermittent preventive therapy during pregnancy (IPTp)
Percent (95% confidence interval [CI]) | ||||
---|---|---|---|---|
Total Public Sector | Private for-profit health facility | Drug store | Total Private Sector | |
N = 92 | N = 367 | N = 741 | N = 3272 | |
Any malaria blood testing | 86.8 (75.9, 93.2) | 75.5 (64.9, 83.7) | 0.3 (0.1, 1.5) | 7.3 (6.1, 8.7) |
Malaria microscopy | 82.9 (72.0, 90.2) | 72.9 (62.8, 81.1) | 0.0 | 7.0 (5.8, 8.3) |
RDT | 21.8 (12.3, 35.8) | 14.0 (10.3, 18.7) | 0.3 (0.1, 1.4) | 1.4 (1.0, 2.0) |
Quality-assured ACT | 28.7 (17.5, 43.2) | 12.5 (8.2, 18.5) | 8.6 (5.5 13.2) | 3.3 (2.5, 4.4) |
Readiness for malaria case management:
Malaria testing and quality-assured ACT available
| 24.5 (15.0, 39.6) | 10.7 (7.2, 15.6) | 0.3 (0.1, 1.5) | 1.1 (0.7, 1.7) |
Readiness for IPTp:
SP available
| 20.2 (11.7, 32.5) | 12.0 (8.1, 17.5) | N/a | N/a |